Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and Vivani Medical (NASDAQ:VANI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Earnings and Valuation
This table compares Verrica Pharmaceuticals and Vivani Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verrica Pharmaceuticals | $35.58 million | 2.64 | -$17.89 million | ($1.58) | -3.46 |
| Vivani Medical | N/A | N/A | -$26.61 million | ($0.43) | -2.51 |
Analyst Ratings
This is a breakdown of current ratings and price targets for Verrica Pharmaceuticals and Vivani Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verrica Pharmaceuticals | 1 | 3 | 1 | 0 | 2.00 |
| Vivani Medical | 1 | 1 | 1 | 0 | 2.00 |
Verrica Pharmaceuticals currently has a consensus target price of $17.00, indicating a potential upside of 210.79%. Vivani Medical has a consensus target price of $3.50, indicating a potential upside of 224.07%. Given Vivani Medical’s higher probable upside, analysts plainly believe Vivani Medical is more favorable than Verrica Pharmaceuticals.
Profitability
This table compares Verrica Pharmaceuticals and Vivani Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verrica Pharmaceuticals | -50.27% | N/A | -40.08% |
| Vivani Medical | N/A | -317.03% | -82.64% |
Insider & Institutional Ownership
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 46.4% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Verrica Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Summary
Verrica Pharmaceuticals beats Vivani Medical on 6 of the 11 factors compared between the two stocks.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
